1 Center for Comprehensive Access and Delivery Research and Evaluation (CADRE), Iowa City VA Medical Center , Iowa City, Iowa.
2 Department of Internal Medicine, University of Iowa , Iowa City, Iowa.
AIDS Patient Care STDS. 2018 Mar;32(3):84-91. doi: 10.1089/apc.2017.0213.
Black persons with HIV are less likely than white persons to experience viral control even while in treatment. We sought to understand whether patient characteristics and site of care explain these differences using a cross-sectional analysis of medical records. Our cohort included 8779 black and 7836 white patients in the Veterans Administration (VA) health system with HIV who received antiretroviral medication during 2013. Our primary outcome, viral control, was defined as HIV serum RNA <200 copies/mL. We examined the degree to which racial differences in viral control are related to site of care, patient characteristics (demographics, HIV treatment history, comorbid conditions, time in care, and medication adherence), retention in care, and combination antiretroviral therapy (cART) adherence, using multi-variable logistic regression models. Compared to whites, blacks were younger and had lower CD4 counts, more comorbidities, lower retention in care, and poorer medication adherence. The odds of uncontrolled viral load were 2.02 (p < 0.001) for black relative to white patients without risk adjustment (15% vs. 8% uncontrolled viral load, respectively). The odds decreased to 1.83 (p < 0.001), 1.65 (p < 0.001), 1.62 (p < 0.001), and 1.24 (p = 0.01) in models that sequentially controlled for site of care, age and clinical characteristics, care retention, and cART adherence, respectively. Overall, 51% of the viral control difference between blacks and whites was accounted for by adherence; 26% by site of care. We conclude that differences in the site of HIV care and cART adherence account for most of the difference in viral control between black and white persons receiving HIV care, although the exact pathway by which this relationship occurs is unknown. Targeting poorer performing sites for quality improvement and focusing on improving antiretroviral adherence in black patients may help alleviate disparities in viral control.
黑人 HIV 感染者在接受治疗时,与白人相比,病毒控制的可能性更小。我们试图通过对退伍军人事务部 (VA) 医疗系统中接受抗逆转录病毒药物治疗的 8779 名黑人患者和 7836 名白人患者的医疗记录进行横断面分析,了解患者特征和治疗地点是否可以解释这些差异。我们的主要结果是病毒控制,定义为 HIV 血清 RNA <200 拷贝/ml。我们使用多变量逻辑回归模型,检查了病毒控制方面的种族差异与治疗地点、患者特征(人口统计学、HIV 治疗史、合并症、在诊时间和药物依从性)、保留在诊和联合抗逆转录病毒治疗(cART)依从性的关系程度。与白人相比,黑人患者更年轻,CD4 计数更低,合并症更多,保留在诊的比例更低,药物依从性更差。未经风险调整时,黑人患者病毒载量失控的几率是白人患者的 2.02 倍(p<0.001)(分别为 15%和 8%病毒载量失控)。在依次控制治疗地点、年龄和临床特征、保留在诊和 cART 依从性的模型中,该比值分别降至 1.83(p<0.001)、1.65(p<0.001)、1.62(p<0.001)和 1.24(p=0.01)。总体而言,黑人与白人患者之间病毒控制差异的 51%归因于药物依从性;26%归因于治疗地点。我们得出的结论是,HIV 治疗地点和 cART 依从性的差异解释了黑人与白人 HIV 感染者之间病毒控制差异的大部分原因,尽管这种关系发生的确切途径尚不清楚。针对表现较差的治疗地点进行质量改进,并专注于提高黑人患者的抗逆转录病毒药物依从性,可能有助于减轻病毒控制方面的差异。